1. Home
  2. IRD vs LTRN Comparison

IRD vs LTRN Comparison

Compare IRD & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • LTRN
  • Stock Information
  • Founded
  • IRD 2018
  • LTRN 2013
  • Country
  • IRD United States
  • LTRN United States
  • Employees
  • IRD N/A
  • LTRN N/A
  • Industry
  • IRD
  • LTRN Biotechnology: Pharmaceutical Preparations
  • Sector
  • IRD
  • LTRN Health Care
  • Exchange
  • IRD NYSE
  • LTRN Nasdaq
  • Market Cap
  • IRD 36.0M
  • LTRN 33.7M
  • IPO Year
  • IRD N/A
  • LTRN 2020
  • Fundamental
  • Price
  • IRD $1.13
  • LTRN $5.01
  • Analyst Decision
  • IRD Strong Buy
  • LTRN Hold
  • Analyst Count
  • IRD 1
  • LTRN 1
  • Target Price
  • IRD $8.00
  • LTRN N/A
  • AVG Volume (30 Days)
  • IRD 144.3K
  • LTRN 167.8K
  • Earning Date
  • IRD 02-24-2025
  • LTRN 03-17-2025
  • Dividend Yield
  • IRD N/A
  • LTRN N/A
  • EPS Growth
  • IRD N/A
  • LTRN N/A
  • EPS
  • IRD N/A
  • LTRN N/A
  • Revenue
  • IRD $8,381,000.00
  • LTRN N/A
  • Revenue This Year
  • IRD N/A
  • LTRN N/A
  • Revenue Next Year
  • IRD $29.37
  • LTRN N/A
  • P/E Ratio
  • IRD N/A
  • LTRN N/A
  • Revenue Growth
  • IRD N/A
  • LTRN N/A
  • 52 Week Low
  • IRD $0.81
  • LTRN $2.79
  • 52 Week High
  • IRD $2.71
  • LTRN $11.99
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • LTRN 58.38
  • Support Level
  • IRD N/A
  • LTRN $4.50
  • Resistance Level
  • IRD N/A
  • LTRN $5.70
  • Average True Range (ATR)
  • IRD 0.00
  • LTRN 0.47
  • MACD
  • IRD 0.00
  • LTRN -0.03
  • Stochastic Oscillator
  • IRD 0.00
  • LTRN 49.26

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

Share on Social Networks: